Back to results
US 6,180,675 B2Granted
IL-8 receptor antagonists
AssigneeSmithKline Beecham Corporation
InventorsKatherine Louisa Widdowson, Daniel Frank Veber, Anthony Joseph Jurewicz, Robert Philip Hertzberg, Melvin Clarence Rutledge, Jr.
Life of this patent
Estimating the term…
Abstract
This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Claims7
A method of treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 α or β receptor in a mammal, which method comprises administering to said mammal an effective amount of a compound of the formula:
- wherein
- X is oxygen or sulfur;
- R is C(O)NR6R7;
- R1 is independently selected from hydrogen;
- halogen;
- nitro;
- cyano;
- halosubstituted C1-10 alkyl;
- C1-10 alkyl;
- C2-10 alkenyl;
- C1-10 alkoxy;
- halosubstituted C1-10 alkoxy;
- azide;
- S(O)tR4;
- hydroxy;
- hydroxy C1-4alkyl;
- aryl;
- aryl C1-4 alkyl;
- aryloxy;
- aryl C1-4 alkyloxy;
- heteroaryl;
- heteroarylalkyl;
- heterocyclic, heterocyclic C1-4alkyl;
- heteroaryl C1-4 alkyloxy;
- arylC2-10alkenyl;
- heteroaryl C2-10 alkenyl;
- heterocyclicC2-10 alkenyl;
- NR4R5;
- C2-10alkenylC(O)NR4R5;
- C(O)NR4R5;
- C(O)NR4R10;
- S(O)3H;
- S(O)3R8;
- C1-10 alkyl C(O)R11;
- C2-10alkenyl C(O)R11;
- C2-10 alkenyl C(O)OR11;
- C(O)R11;
- C(O)OR12;
- OC(O)R11;
- NR4C(O)R11;
- or two R1 moieties together may form O—(CH2)sO— or a 5 to 6 membered unsaturated ring;
- t is 0, or an integer having a value of 1 or 2;
- s is an integer having a value of 1 to 3;
- R4 and R5 are independently hydrogen, optionally substituted C1-4 alkyl, optionally substituted aryl, optionally substituted aryl C1-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C1-4alkyl, heterocyclic, heterocyclic C1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S;
- R6 and R7 are independently hydrogen or a C1-4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
- Y is independently selected from hydrogen;
- halogen;
- nitro;
- cyano;
- halosubstituted C1-10 alkyl;
- C1-10 alkyl;
- C2-10 alkenyl;
- C1-10 alkoxy;
- halosubstituted C1-10 alkoxy;
- azide;
- S(O)tR4;
- hydroxy;
- hydroxyC1-4alkyl;
- aryl;
- aryl C1-4 alkyl;
- aryloxy;
- arylC1-4 alkyloxy;
- heteroaryl;
- heteroarylalkyl;
- heteroarylC1-4 alkyloxy;
- heterocyclic, heterocyclicC1-4alkyl;
- arylC2-10alkenyl;
- heteroaryl C2-10 alkenyl;
- heterocyclicC2-10 alkenyl;
- NR4R5;
- C2-10alkenylC(O)NR4R5;
- C(O)NR4R5;
- C(O)NR4R10;
- [S(O)3H;] S(O)3R8;
- C1-10alkylC(O)R11;
- C2-10 alkenyl C(O)R11;
- C2-10 alkenyl C(O)OR11;
- C(O)R11;
- C(O)OR12;
- OC(O)R11;
- NR4C(O)R11;
- or two Y moieties together may form O—(CH2)sO— or a 5 to 6 membered unsaturated ring;
- n is an integer having a value of 1 to 3;
- m is an integer having a value of 1 to 3;
- R8 is hydrogen or C1-4 alkyl;
- R10 is C1-10 alkyl C(O)2R8;
- R11 is hydrogen, C1-4 alkyl, optionally substituted aryl, optionally substituted aryl C1-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C1-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclic C1-4alkyl;
- R12 is hydrogen, C1-10 alkyl, optionally substituted aryl or optionally substituted arylalkyl;
- or a pharmaceutically acceptable salt thereof.
86 more elements
Dependencies are inferred from the claim text.